Introduction to NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) is a clinical-stage biotechnology company headquartered in Emeryville, California, that focuses on developing and commercializing innovative, non-antibiotic antimicrobial therapies for a range of serious infectious diseases. Founded in 2000, the company has carved out a distinctive niche in the healthcare landscape by leveraging its proprietary Avenova® technology—a hypochlorous acid (HOCl) solution proven to kill bacteria, viruses, and fungi without promoting antibiotic resistance. With a market capitalization of approximately $20 million and annual revenue of around $10 million (as of 2023), NovaBay operates at the intersection of ophthalmology, dermatology, and wound care, serving hospitals, clinics, and surgical centers worldwide. The NovaBay Pharmaceuticals company profile emphasizes scientific rigor, patient safety, and a robust pipeline that includes Avenova® (lid and lash hygiene), Neuac® (acne treatment), and Phase 2 candidates for diabetic foot ulcers and recurrent urinary tract infections. Recognized as a top healthcare innovator, NovaBay has earned partnerships with major medical distributors such as McKesson and Cardinal Health, underscoring its credibility and reach. Organizations choose NovaBay for its commitment to evidence-based medicine, regulatory excellence (FDA-cleared products), and a corporate culture that prioritizes transparency and collaboration. This profile explores every facet of NovaBay Pharmaceuticals—from its origins and evolution to its leadership philosophy and future roadmap—providing a comprehensive resource for job seekers, investors, and healthcare professionals.
Company History and Business Evolution
NovaBay Pharmaceuticals was founded in 2000 by Dr. R. Scott H. (full name: Ronald Scott Hyman), a serial entrepreneur and scientist who recognized the growing threat of antibiotic resistance. The company’s early years were dedicated to developing a novel class of antimicrobial compounds, culminating in the discovery of Avenova® (neutrophil-generated hypochlorous acid) in 2005. This breakthrough led to an initial public offering (IPO) on the American Stock Exchange in 2006, raising $25 million to fund clinical trials. A pivotal milestone came in 2008 when NovaBay received FDA clearance for Avenova® as a medical device for cleansing the ocular surface, launching its first commercial product. The following decade saw strategic expansions: in 2012, NovaBay acquired the rights to Neuac® from Valeant Pharmaceuticals, entering the dermatology market; in 2015, the company launched a Phase 2 trial for Avenova® in diabetic foot ulcers; and in 2018, it secured a patent for its HOCl technology in the European Union. The COVID-19 pandemic accelerated demand for non-antibiotic antimicrobials, and NovaBay reported a 40% revenue increase in 2020. However, the company faced challenges with inventory management and a 2021 SEC investigation (later resolved without penalties), yet emerged stronger with a refocused pipeline. In 2022, NovaBay announced a partnership with the University of California, San Francisco to study Avenova® for preventing hospital-acquired infections, and in 2023, it initiated a pivotal Phase 3 trial for recurrent UTIs. Today, NovaBay employs approximately 50 people (2024 estimate) and maintains a lean, agile operational model that allows rapid innovation while controlling costs. The NovaBay Pharmaceuticals company history reflects a persistent pursuit of safe, effective antimicrobial solutions in a world grappling with superbugs.
NovaBay Pharmaceuticals at a Glance
- Headquarters: Emeryville, California, USA
- Founded: 2000 by Dr. Ronald Scott Hyman
- CEO: Justin Hall (as of 2024)
- Revenue: ~$10 million (TTM 2023)
- Employees: ~50 full-time
- Stock Ticker: NBY (NYSE American)
- Key Product: Avenova® (hypochlorous acid solution)
- Other Products: Neuac® (acne treatment), Avenova® for wound care
- Pipeline: Phase 3 for recurrent UTI; Phase 2 for diabetic foot ulcers
- FDA Clearances: Multiple 510(k) clearances for medical devices
- Patents: 15+ issued worldwide
- Major Partners: McKesson, Cardinal Health, Henry Schein
- Competitors: Oculus, Bausch + Lomb, Pfizer (non-antibiotic space)
- Market Focus: Ophthalmology, dermatology, wound care
- Global Reach: Products sold in over 10 countries
- Awards: 2023 Innovation Award from the American Society of Ophthalmic Administrators
- Corporate Status: Public company (NBY)
- Scientific Advisory Board: Includes experts from Harvard, Stanford
- Clinical Trials: Over 500 patients enrolled in company-sponsored studies
Mission, Vision, and Core Corporate Values
NovaBay Pharmaceuticals’ mission is to ‘discover, develop, and commercialize innovative non-antibiotic antimicrobial solutions that effectively treat infections while preserving the microbiome and preventing resistance.’ The company’s vision is to become the global leader in hypochlorous acid-based therapeutics, transforming the standard of care for ophthalmic, dermatologic, and wound infections. Core corporate values include:
- Integrity: Conducting all clinical and business activities with transparency and ethical rigor.
- Innovation: Continually pursuing novel applications of HOCl technology.
- Patient Centricity: Putting patient safety and outcomes at the heart of every decision.
- Collaboration: Partnering with healthcare providers, researchers, and regulators to accelerate impact.
- Sustainability: Developing environmentally friendly manufacturing processes and reducing antibiotic overuse.
These values are embedded in daily operations, from R&D protocols to employee performance reviews. NovaBay’s commitment to ‘One Health’—recognizing the link between human, animal, and environmental health—guides its long-term strategy.
Business Strategy and Future Roadmap
NovaBay Pharmaceuticals pursues a dual-track strategy: advancing its late-stage pipeline while maximizing commercial revenue from existing products. The immediate priority is completing the Phase 3 trial for Avenova® in recurrent urinary tract infections (UTI), a condition affecting millions annually with limited non-antibiotic options. If successful, the company aims to submit a New Drug Application (NDA) to the FDA by 2026, potentially achieving blockbuster status. Concurrently, NovaBay is expanding Avenova®’s label for chronic venous leg ulcers through a Phase 2b study. On the commercial front, the company is optimizing distribution channels in ophthalmology, where Avenova® is already the 1 prescribed lid hygiene product among optometrists. Future plans include entering the veterinary market (HOCl solutions for animal skin infections) and developing a sustained-release formulation for surgical site infections. NovaBay also invests in digital health tools, such as a mobile app for dry eye disease management to boost patient adherence. The roadmap includes geographic expansion into Asia-Pacific through licensing deals, with a target of $50 million in revenue by 2027. Key initiatives:
- Clinical: Phase 3 UTI trial completion (2024-2025).
- Regulatory: NDA submission for UTI indication (2026).
- Commercial: Launch of Avenova® in Japan (2025).
- R&D: HOCl-based spray for influenza inactivation (pre-clinical).
- Partnerships: Out-licensing rights for wound care in Europe.
Products, Technologies, and Services
NovaBay’s core technology is pure hypochlorous acid (HOCl) generated by its proprietary electrochemical process. Unlike bleach, NovaBay’s HOCl is bioequivalent to the molecule produced by human neutrophils, making it safe for delicate tissues while being powerfully antimicrobial. Key products include:
- Avenova® (ophthalmic solution): FDA-cleared for lid hygiene, blepharitis, dry eye, and pre-surgical antisepsis. Available as a spray and wipes.
- Neuac® (topical acne treatment): A combination of clindamycin and tretinoin in a patented gel, targeting moderate-to-severe acne.
- Avenova® Wound Care: 0.01% HOCl solution for irrigation and debridement of acute and chronic wounds.
- Pipeline: UTI suppository, diabetic foot ulcer foam.
The company also provides contract manufacturing services for other biotech firms seeking HOCl formulations. NovaBay’s services include custom formulation development, stability testing, and regulatory support, leveraging its GMP-certified facility in Emeryville.
Industries and Markets Served
NovaBay primarily serves the healthcare industry across three verticals: ophthalmology (optometrists, ophthalmologists, hospitals), dermatology (dermatologists, aesthetic clinics), and wound care (podiatrists, wound care centers, long-term care facilities). The company also targets the veterinary market through distributors like Covetrus. Key customer segments include:
- Hospital systems (e.g., Kaiser Permanente, HCA Healthcare)
- Optometry chains (Pearle Vision, LensCrafters)
- Dermatology clinics (<50% of revenue)
- Government military (for combat wound care)
Geographically, the U.S. represents 90% of sales, but Canada, the UK, and Australia are growing due to recent approvals.
Leadership and Management Philosophy
NovaBay’s leadership team combines deep biotech expertise with a pragmatic, hands-on approach. CEO Justin Hall (since 2022) previously held senior roles at Allergan and Novartis, championing a culture of accountability and speed. The management philosophy centers on three pillars: Execution Excellence (meeting clinical milestones), Employee Empowerment (flat organizational structure), and Stakeholder Transparency (quarterly investor calls, open-door policy). The board includes Dr. David A. Harding (former FDA official) and Dr. Karin Hehenberger (founder of Lyfebulb), ensuring strategic oversight. NovaBay encourages entrepreneurial thinking: all employees have access to the CEO’s calendar and participate in monthly ‘Innovation Forums.’
Corporate Events, Conferences, and Community Engagement
NovaBay actively participates in major industry conferences such as AAO (American Academy of Ophthalmology), AAD (American Academy of Dermatology), and Wound Healing Society (WHS) meetings. The company also hosts annual ‘Avenova® Symposia’ for optometrists, featuring KOL speakers. In the community, NovaBay supports local STEM education through its ‘Science for Sight’ program, donating a portion of profits to vision screenings in underserved schools. Employee volunteer days focus on environmental cleanups and mentoring aspiring scientists.
Employees and Workplace Culture
With ~50 employees, NovaBay fosters a start-up-like atmosphere within a public company framework. The culture emphasizes flexibility (hybrid remote policy), collaboration (cross-functional project teams), and wellness (onsite gym, mental health days). Benefits include 401(k) matching, stock options, health insurance, and a $5,000 annual education stipend. Glassdoor reviews (average 4.1/5) praise the ‘mission-driven environment’ and supportive management. Turnover is low (around 10% annually). Diversity metrics: 45% women, 35% minorities in management positions (2023 report).
Job Details & Requirements for this Posting
Position: Senior Clinical Research Associate (Healthcare)
- Location: Remote (USA) or Emeryville, CA Hub
- Reports to: VP of Clinical Operations
- Salary Range: $110,000 – $135,000
- Job Type: Full-time, with occasional travel (20%)
Role Description
We are seeking a Senior CRA to lead clinical trial monitoring activities for our late-phase studies in ophthalmology and infectious disease. You will ensure site compliance, data integrity, and patient safety across 15+ investigational sites in the U.S.
Responsibilities
- Conduct site qualification, initiation, routine monitoring, and close-out visits.
- Review source documents, verify CRF entries against source data, and ensure regulatory binder completeness.
- Manage site communication, training, and issue escalation.
- Collaborate with data management and biostatistics to resolve queries.
- Author monitoring summaries and contribute to clinical study reports.
Qualifications
- BA/BS in life sciences (MS preferred).
- 3+ years of CRA experience, preferably in ophthalmology or dermatology.
- Thorough knowledge of ICH-GCP, FDA regulations.
- Excellent organizational, communication, and problem-solving skills.
- Ability to travel up to 30% (car/air).
Why Join NovaBay Pharmaceuticals?
Be part of a mission-driven team combatting antibiotic resistance. You’ll have direct impact on late-stage development, work flexible hours, and receive a competitive compensation package including stock options. NovaBay offers rapid career growth: 70% of our CRAs have been promoted within 2 years. Additionally, you’ll work with top-tier principal investigators and gain exposure to regulatory interactions.
Customer Reviews and Industry Reputation
NovaBay Pharmaceuticals’ reputation is shaped by clinical evidence, regulatory successes, and word-of-mouth among healthcare professionals. Below we analyze feedback from major platforms, totaling over 1,200 words.
Glassdoor
On Glassdoor, NovaBay has approximately 30 reviews, with an overall rating of 4.1 out of 5. Employees highlight the collaborative culture and meaningful work. Common praises: ‘Executives listen to ideas,’ ‘Flexibility is unmatched.’ Criticisms include budget constraints causing slower promotions. Recent review (2023): ‘Great place if you want to make a difference but be prepared for limited resources.’ Response rate from HR is high, showing engagement.
Indeed
Indeed shows a 3.9 average from 18 reviews. Many call out the friendly team atmosphere and strong ethics. One reviewer notes: ‘I love that we are actually helping patients with real infections.’ Negative comments focus on older facilities (Emeryville office is dated). Indeed recommends NovaBay as a ‘good stepping stone for early career scientists.’
Gartner Peer Insights
While Gartner does not cover micro-cap biotech extensively, NovaBay has 5 ratings in the ‘Healthcare Provider Solutions’ category, averaging 4.3. Customers (hospitals) appreciate the efficacy of Avenova® in reducing surgical site infections, with one comment: ‘Reduced our infection rate by 60% compared to iodine.’
Trustpilot
Trustpilot features 22 reviews from consumers using Avenova® for dry eye. Average rating: 4.5 stars. Users report ‘instant relief’ and ‘no stinging.’ Negative feedback includes price ($25/bottle) and difficulty finding in stores. Company responds to all negative reviews, offering refunds.
G2
Not applicable – NovaBay does not sell software. However, their contract manufacturing service has 2 reviews on G2’s ‘Life Sciences Services’ page, scoring 4.6 for quality and reliability.
Google Reviews
Google My Business for NovaBay’s Emeryville HQ shows 4.2 stars based on 12 reviews. Patients and suppliers praise ‘fast shipping’ and ‘caring customer service.’ One complaint about unresponsive billing; addressed by management.
LinkedIn Reputation
NovaBay’s LinkedIn page (4,500+ followers) generates positive sentiment. Employees post about product launches, and the company’s ‘Culture’ showcase features photos from volunteer events. LinkedIn’s ‘Life’ tab highlights a 4.0 employer brand rating (scale of 5). Skills most associated: clinical research, biotechnology, regulatory affairs.
Why Organizations Choose NovaBay Pharmaceuticals
Healthcare organizations select NovaBay for proven efficacy (FDA-cleared products), innovative technology (non-antibiotic HOCl), and patient outcomes. Hospitals using Avenova® for pre-surgical antisepsis report 40% fewer infections. Optometry chains choose it as a dry eye treatment with strong reimbursement (CPT code). The ability to customize formulations (e.g., higher HOCl concentration for wound care) adds flexibility. Overall, NovaBay offers a lower total cost of care compared to antibiotics, while addressing the global resistance crisis.
Official Contact Information
For inquiries and assistance, please reach out to NovaBay Pharmaceuticals using the following contact details:
Address: 2000 Powell Street, Suite 300, Emeryville, CA 94608, USA
Contact Number: +1-510-899-8800
Support Number: +1-888-667-4002 (toll-free)
Helpdesk Number: +1-510-899-8800 ext. 2
Website: www.novabaypharma.com
Official Social Media Presence
- LinkedIn: @NovaBayPharmaceuticals
- Twitter: @novabaypharma
- Facebook: NovabayPharma
- YouTube: NovaBay Pharmaceuticals
- Instagram: @novabaypharma
SEO FAQ Section
1. What is NovaBay Pharmaceuticals known for?NovaBay Pharmaceuticals is known for its non-antibiotic antimicrobial solutions, particularly Avenova® for eye infections and wound care. The company focuses on hypochlorous acid technology to combat antibiotic resistance.
2. Where is NovaBay Pharmaceuticals headquartered?NovaBay Pharmaceuticals is headquartered in Emeryville, California, USA.
3. Who is the CEO of NovaBay Pharmaceuticals?Justin Hall serves as CEO of NovaBay Pharmaceuticals as of 2024.
4. What products does NovaBay Pharmaceuticals offer?Key products include Avenova® (lid cleanser), Neuac® (acne gel), and Avenova® Wound Care solution.
5. Is NovaBay Pharmaceuticals a public company?Yes, it trades on the NYSE American under ticker NBY.
6. What clinical trials is NovaBay Pharmaceuticals conducting?Phase 3 trial for recurrent urinary tract infections, Phase 2 for diabetic foot ulcers.
7. How does NovaBay Pharmaceuticals address antibiotic resistance?By developing antimicrobials that are not antibiotics, using HOCl that does not promote resistance.
8. What is Avenova® made of?Avenova® contains pure hypochlorous acid (HOCl) at a concentration of 0.01%, stabilized in a saline solution.
9. Does NovaBay Pharmaceuticals have any partnerships?Yes, with McKesson, Cardinal Health, Kaiser Permanente, and UCSF.
10. How many employees does NovaBay Pharmaceuticals have?Approximately 50 full-time employees as of 2024.
11. What is the revenue of NovaBay Pharmaceuticals?Estimated $10 million for fiscal year 2023.
12. What infections does Avenova® treat?It is FDA-cleared for blepharitis, dry eye, and pre-operative antisepsis; off-label use for skin infections.
13. Is NovaBay Pharmaceuticals profitable?No, it is a clinical-stage company with net losses, typical for biotech.
14. What is the company’s mission?‘To discover, develop, and commercialize innovative non-antibiotic antimicrobial solutions.’
15. Does NovaBay Pharmaceuticals offer jobs remotely?Yes, many roles including this CRA position are remote-friendly.
16. What is the working culture like at NovaBay Pharmaceuticals?Collaborative, flexible, mission-driven, with flat hierarchy.
17. How can I contact NovaBay Pharmaceuticals investor relations?Via the contact page at novabaypharma.com or email investorrelations@novabaypharma.com.
18. Has NovaBay received FDA warnings?No significant FDA warning letters; occasional form 483 observations resolved.
19. What is the stock symbol for NovaBay?NBY on NYSE American.
20. How can I buy Avenova® products?Through optometrists, online pharmacies (e.g., Amazon), or directly from novabaypharma.com.
To further explore the biotech and healthcare content landscape, consider leveraging industry resources. NovaBay Pharmaceuticals (visit the official website at www.novabaypharma.com) offers a deep dive into its pioneering antimicrobial technology. For those seeking to enhance their online presence through quality backlinks, consider engaging a Guest Post Service Provider like Lockurblock, which specializes in dental, health, and biotech niches. Such partnerships can amplify brand awareness and drive targeted traffic to your corporate blog.
", "location": "Emeryville, California (Remote eligible)", "salary": "$110,000 – $135,000 per year", "job_type": "Full-time"}